🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

102+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 102 recruiting trials for “perihilar-cholangiocarcinoma

Enrolling by InvitationNCT05429190

Validation of SMS Protocol for HCC Screening in High-risk Patients

👨‍⚕️ Prof. Dr. de Man, Erasmus Medical Center📍 6 sites📅 Started Nov 2023View details ↗
Phase 1RecruitingNCT06010862

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

👨‍⚕️ Fei Li, M.D, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Sep 2023View details ↗
Phase 3RecruitingNCT05823311

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Sep 2023View details ↗
Phase 1, PHASE2RecruitingNCT05874414

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

👨‍⚕️ Peter Lichten, M.D., Genfit📍 11 sites📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT05451043

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

🏥 AHS Cancer Control Alberta📍 1 site📅 Started Jul 2023View details ↗
RecruitingNCT06899854

Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.

🏥 Fondazione IRCCS Policlinico San Matteo di Pavia📍 1 site📅 Started Jun 2023View details ↗
Phase 2RecruitingNCT06335927

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

🏥 Fudan University📍 1 site📅 Started May 2023View details ↗
Phase 3RecruitingNCT05876754

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

🏥 Servier Affaires Médicales📍 84 sites📅 Started May 2023View details ↗
Phase 1RecruitingNCT05568680

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

👨‍⚕️ Laura Johnson, PhD, Verismo Therapeutics📍 4 sites📅 Started Mar 2023View details ↗
NARecruitingNCT05764551

The Application of Serum DNA Methylation for Patients With HCC

👨‍⚕️ Po-Yueh Chen, M.D, Ditmanson Medical Foundation Chiayi Christian Hospital📍 1 site📅 Started Mar 2023View details ↗
Phase 4RecruitingNCT05551299

Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy

👨‍⚕️ Albrecht Hoffmeister, Prof.Dr.med., Universitätsklinikum Leipzig; Bereich Gastroenterologie📍 20 sites📅 Started Feb 2023View details ↗
NARecruitingNCT06964425

Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study

👨‍⚕️ Peter Slodička, M.D., University Hospital Olomouc📍 1 site📅 Started Feb 2023View details ↗
NARecruitingNCT05957250

[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer

👨‍⚕️ Rutger-Jan Swijnenburg, MD, PhD, Amsterdam UMC, location AMC📍 1 site📅 Started Feb 2023View details ↗
Phase 2RecruitingNCT05430698

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

👨‍⚕️ Chao Liu, PhD, Department of Biliary and Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University📍 1 site📅 Started Jan 2023View details ↗
Phase 2RecruitingNCT05625893

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

👨‍⚕️ Jeong Il Yu, MD, PhD, Samsung Medical Center📍 1 site📅 Started Jan 2023View details ↗
Phase 2RecruitingNCT05678270

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

👨‍⚕️ Jin Li, Shanghai East Hospital📍 44 sites📅 Started Nov 2022View details ↗
Phase 1RecruitingNCT05285358

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

👨‍⚕️ Daneng Li, MD, City of Hope Medical Center📍 1 site📅 Started Sep 2022View details ↗
NARecruitingNCT05443087

TARGETed Therapy Drug MONITOring in DIGestive Oncology

👨‍⚕️ David MALKA, Dr, Gustave ROUSSY - VILLEJUIF📍 29 sites📅 Started Aug 2022View details ↗
Phase 4RecruitingNCT05124002

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

👨‍⚕️ ZHANG YUEWEI, MD, Beijing Tsinghua Chang Gung Hospital📍 1 site📅 Started Aug 2022View details ↗
NARecruitingNCT05053555

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

👨‍⚕️ Joshua Kuban, M.D. Anderson Cancer Center📍 1 site📅 Started Apr 2022View details ↗
← PreviousPage 4 of 6Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →